IMUX

Immunic Inc

Add to Watchlist

Advanced Chart

0.891

-0.026(-2.830%)

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.9413

Open

0.920

VWAP

0.92

Vol

629.12K

Mkt Cap

87.92M

Low

0.8843

Amount

577.27K

EV/EBITDA(TTM)

Total Shares

90.08M

73.62M

EV/OCF(TTM)

P/S(TTM)

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Company’s s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.177

-29.14%

-0.179

-25.6%

-0.191

-8.84%

Estimates Revision

The market is revising No Change the revenue expectations for Immunic, Inc. (IMUX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -20.42%.

EPS Estimates for FY2025

Revise Upward

+6.75%

In Past 3 Month

Stock Price

Go Down

-20.42%

In Past 3 Month

6 Analyst Rating

1515.62% Upside

Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 14.40 USD with a low forecast of 6.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

1515.62% Upside

Current: 0.891

Low

6.00

Averages

14.40

High

28.00

1515.62% Upside

Current: 0.891

Low

6.00

Averages

14.40

High

28.00

B. Riley Securities

William Woods

Strong Buy

Reiterates

$6 → $5

2025-05-23

New

Reason

B. Riley Securities

William Woods

Price Target

$6 → $5

2025-05-23

New

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$10

2025-05-01

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$10

2025-05-01

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-04-30

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-04-30

Maintains

Strong Buy

Reason

B. Riley Securities

William Woods

Strong Buy

Reiterates

2025-04-16

Reason

B. Riley Securities

William Woods

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Matthew Caufield

Strong Buy

Reiterates

$10

2025-04-15

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

$10

2025-04-15

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$17

2025-04-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

$17

2025-04-10

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Immunic Inc (IMUX.O) is -1.24, compared to its 5-year average forward P/E of -2.55. For a more detailed relative valuation and DCF analysis to assess Immunic Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.55

Current PE

-1.24

Overvalued PE

-0.59

Undervalued PE

-4.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

19.84

Current EV/EBITDA

849.83

Overvalued EV/EBITDA

133.33

Undervalued EV/EBITDA

-93.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1208.68

Current PS

0.00

Overvalued PS

4751.57

Undervalued PS

-2334.21

Financials

Annual

Quarterly

FY2025Q1

YoY :

+12.33%

-26.83M

Operating Profit

FY2025Q1

YoY :

-13.90%

-25.47M

Net Income after Tax

FY2025Q1

YoY :

-16.67%

-0.25

EPS - Diluted

FY2025Q1

YoY :

-9.07%

-21.82M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

100.4K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.0M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

100.4K

USD

Months

0-12

0.0

USD

Months

IMUX News & Events

Events Timeline

2025-04-30 (ET)

2025-04-30

07:38:23

Immunic's vidofludimus calcium shows positive results in Phase 2 PMS trial

2025-04-09 (ET)

2025-04-09

08:36:49

Immunic sells 5.67M shares at 90c in registered direct offering

2025-02-20 (ET)

2025-02-20

07:35:06

Immunic announces IMU-856 demonstrated dose-dependent increase

News

1.0

05-02Newsfilter

Immunic to Participate in Scientific and Industry Conferences in May

9.0

04-30Newsfilter

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

9.0

04-30SeekingAlpha

Immunic drops after mid-stage trial data for multiple sclerosis drug